Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 17, Issue 3, 2016, Pages

  Persson, Frederik ^a   Lindhardt, Morten ^a   Rossing, Peter ^a,c   Parving, Hans Henrik ^b,d  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Diabetic nephropathy; Microalbuminuria; Renin angiotensin system; Review; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL;

DRUG EFFICACY; EARLY INTERVENTION; FOLLOW UP; HUMAN; META ANALYSIS; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; ALBUMINURIA; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HYPERTENSION; PATHOPHYSIOLOGY; PUBLISHING;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; PUBLICATION BIAS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84983316556     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320316652047     Document Type: Review

References (44)

1. Parving H-H, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int 2006; 69: 2057-2063
2. Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Diabetes Care 2016; 39: S107-S108
3. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004; 351: 1941-1951
4. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet 2008; 372: 1385-1393
5. Haller H, Ito S, Izzo JL, Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
6. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: A systematic review and meta-analysis. CMAJ 2013; 185: 949-957
7. Parving HH, Gall MA, Skott P, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762
8. Christensen PK, Larsen S, Horn T, et al. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int 2000; 58: 1719-1731
9. Rossing P, Feldt-Rasmussen B and Parving H-H. Diabetic nephropathy. Brenner and Rector's The kidney. 10th ed. Elsevier 2015, p. 1283
10. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J 2011; 343: d5928
11. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
12. Demets DL. Methods for combining randomized clinical trials: Strengths and limitations. Stat Med 1987; 6: 341-350
13. Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61: 64-75
14. Thorlund K, Devereaux PJ, Wetterslev J, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 2009; 38: 276-286
15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34
16. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attennuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 1998; 128: 982-988
17. HOPE trial investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259
18. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007; 370: 829-840
19. Schievink B, Kropelin T, Mulder S, et al. Early reninangiotensin- system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes Metab 2016; 18: 64-71
20. Hellemons ME, Persson F, Bakker SJL, et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria. Diabetes Care 2011; 34: 2078-2083
21. Gaede P, Tarnow L, Vedel P, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784-2788
22. Parving H-H, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 Diabetes. N Engl J Med 2001; 345: 870-878
23. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
24. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
25. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930
26. Strippoli GF, Craig M, Schena FP, et al. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 3081-3091
27. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network metaanalysis. Lancet 2015; 385: 2047-2056
28. Catala-Lopez F, Macias Saint-Gerons D, Gonzalez-Bermejo D, et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: A systematic review with network meta-analyses. PLoS Med 2016; 13: e1001971
29. Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: Systematic review and meta-analysis of randomized trials. Br Med J 2016; 352: i438
30. Lindhardt M, Persson F, Currie G, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): Essential study design and rationale of a randomised clinical multicentre trial. BMJ Open 2016; 6: e010310
31. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402
32. Wang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetic retinopathy: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015; 3: 263-274
33. Parving HH and Persson F. Effects of RAS inhibitors on diabetic retinopathy. Lancet Diabetes Endocrinol 2015; 3: 315-316
34. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
35. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, ran- domised, double-blind, controlled trial. Lancet 2008; 372: 547-553
36. Schjoedt KJ, Astrup AS, Persson F, et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: A randomised crossover trial. Diabetologia 2009; 52: 46-49
37. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198
38. Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926
39. Kropelin TF, de Zeeuw D, Remuzzi G, et al. Determining the optimal protocol for measuring an albuminuria class transition in clinical trials in diabetic kidney disease. J Am Soc Nephrol. Epub ahead of print 7 April 2016. doi: 10.1681/ASN.2015101150
40. Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int 2007; 72: 879-885
41. Barnett AH, Bain SC, Bouter P, et al. Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961
42. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51
43. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697
44. Stewart GB, Altman DG, Askie LM, et al. Statistical analysis of individual participant data meta-analyses: A comparison of methods and recommendations for practice. PloS One 2012; 7: e46042